Kite Pharma Inc (KITE) Holdings Reduced by California Public Employees Retirement System
California Public Employees Retirement System lowered its holdings in Kite Pharma Inc (NASDAQ:KITE) by 94.7% in the third quarter, HoldingsChannel.com reports. The fund owned 4,519 shares of the biopharmaceutical company’s stock after selling 80,481 shares during the quarter. California Public Employees Retirement System’s holdings in Kite Pharma were worth $813,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in the business. Evercore Wealth Management LLC acquired a new position in shares of Kite Pharma during the 3rd quarter worth $153,000. LMR Partners LLP acquired a new position in shares of Kite Pharma during the 3rd quarter worth $200,000. Comerica Bank acquired a new position in shares of Kite Pharma during the 2nd quarter worth $201,000. Virtu Financial LLC acquired a new position in shares of Kite Pharma during the 3rd quarter worth $255,000. Finally, Zeke Capital Advisors LLC acquired a new position in shares of Kite Pharma during the 3rd quarter worth $284,000. 87.72% of the stock is owned by institutional investors.
Kite Pharma Inc (NASDAQ KITE) opened at $179.99 on Friday. The stock has a market capitalization of $10,280.00 and a price-to-earnings ratio of -26.06. Kite Pharma Inc has a one year low of $39.82 and a one year high of $179.99.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.watchlistnews.com/kite-pharma-inc-kite-holdings-reduced-by-california-public-employees-retirement-system/1825006.html.
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Want to see what other hedge funds are holding KITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kite Pharma Inc (NASDAQ:KITE).
Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.